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a b s t r a c t
This paper reports the characterization of an electrochemical biosensor for the continuous monitoring
of Naproxen based on cytochrome P450. The electrochemical biosensor is based on the drop-casting
of multi-walled carbon-nanotubes (MWCNTs) and microsomal cytochrome P4501A2 (msCYP1A2) on
a graphite screen-printed electrode (SPE).
The proposed biosensor was employed to monitor Naproxen (NAP), a well-known anti-inﬂammatory
compound, through cyclic voltammetry. The dynamic linear range for the amperometric detection of NAP
had an upper limit of 300 mMwith a corresponding limit of detection (LOD) of 1671 mM (S/N¼3), which
is included in NAP physiological range (9–300 mM). The MWCNT/msCYP1A2-SPE sensor was also
calibrated for NAP detection in mouse serum that was previously extracted from mice, showing a
slightly higher LOD (33718 mM).
The stability of the msCYP1A2-based biosensor was assessed by longtime continuous cyclic
voltammetric measurements. The ability of the sensor to monitor drug delivery was investigated by
using a commercial micro-osmotic pump. Results show that the MWCNT/msCYP1A2-SPE sensor is
capable of precisely monitoring the real-time delivery of NAP for 16 h. This work proves that the
proposed electrochemical sensor might represent an innovative point-of-care solution for the persona-
lization of drug therapies, as well as for pharmacokinetic studies in both animals and humans.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
In the last decades, many efforts have been focused on the
development of new technologies for personalized medical diagnos-
tics (Hamburg and Collins, 2010). The main reasons are the urgency
to increase the efﬁcacy of therapies, with a drastic reduction of
adverse drug reactions and to reduce the unnecessary costs asso-
ciated with ineffective therapies (Aspinall and Hamermesh, 2007).
The therapeutic drug monitoring (TDM) is a discipline based on
the precise quantiﬁcation of drug concentration after administra-
tion, and on the individual drug dose adjustment according to the
pharmacokinetics proﬁle (Gross, 2002). However, despite its advan-
tages, the TMD is restricted to few facilities mainly because the
current analytical techniques (e.g. chromatography, mass spectro-
scopy and immunoassay) require highly trained personnel and
speciﬁc equipment, high costs, extensive sample preparation and
time consuming pre-concentration steps (Hiemke, 2008).
For this reason, the TDM practice can greatly beneﬁt from the
introduction of electrochemical biosensors owing to their portability,
speed, low-cost and enhanced speciﬁcity (Wang, 2006), which can
both simplify patients' compliance and reduce the cost of hospitali-
zation (D'Orazio, 2011).
Enzymatic amperometric biosensors for drug monitoring have
recently attracted considerable attention due to their potential in
clinical applications (Wang, 1999; Hendricks et al., 2009). One
approach is the use of cytochrome P450 enzyme (CYP), whose best
features are its capability to detect non-electroactive drugs and a
broad substrate range (Schneider and Clark, 2013).
The limitation with CYP biosensors is the necessity to deal with
the low efﬁciency of the electrochemical coupling between protein
and electrode, and to investigate the protein stability in time
(Sadeghi et al., 2011).
This article reports an investigation on the performances of an
electrochemical biosensor based on multi-walled carbon-nanotubes
(MWCNTs), microsomal cytochrome P4501A2 (msCYP1A2) and gra-
phite SPE for the sensitive monitoring of a drug continuously delivered
by an osmotic pump. The measured drug is Naproxen (NAP), a non-
steroidal anti-inﬂammatory agent with analgesic and antipyretic
properties, widely used for mild to moderate pain relief and in the
treatment of osteo- and rheumatoid arthritis (Anttila et al., 1980).
MWCNTs have been recognized as very promising nanomater-
ials for enhancing electron transfer in biosensing (Wang, 2005).
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Previously, MWCNTs were shown to play a key role in enhancing
the electrocatalytic current of CYP (Carrara et al., 2011) and also for
drugs detection (Baj-Rossi et al., 2012). msCYP1A2 was used since
it has been discovered that microsomes are as effective as
recombinant CYP in mediating electrocatalysis of substrates
(Sultana et al., 2005, Mie et al., 2009), they are easier to produce
than recombinant CYP, are largely used in the industry for drug
development (Schneider and Clark, 2013), and they do not require
speciﬁc pre-treatments.
In this work, the duration of enzymatic activity of msCYP1A2
was ﬁrst assessed by long-time continuous cyclic voltammetric
measurements. The ability of the sensor to monitor drug delivery
was investigated by means of a commercial micro-osmotic pump.
The MWCNT/msCYP1A2-SPE sensor was successfully applied to
the real-time monitoring of NAP for 16 h. The results show that
this electrochemical sensor provides high sensitivity and extreme
simplicity in sensor preparation, all features that are suitable for
the development of a point-of-care sensor making this approach a
good candidate for the development of a fully operational ther-
apeutic biosensor that might be in future useful in TDM practice.
2. Experimental
2.1. Reagents and chemicals
The biosensors were prepared using commercial carbon paste SPEs
(model DRP-C110, DropSens, Llanera, Spain) consisting of a graphite
working electrode with an active area of 12.54mm2, a graphite
counter electrode and a Ag|AgCl reference electrode. MWCNTs
(E10 nm diameter and E1–2mm length) were purchased as a
powder from DropSens. A 1 mg/ml solution of MWCNTs, prepared
in chloroform, was sonicated for 30 min to obtain a homogeneous
suspension (Carrara et al., 2011). The msCYP1A2 (Sigma-Aldrich, St.
Gallen, Switzerland) purchased as isozyme microsomes with recom-
binant human CYP1A2, recombinant rabbit NADPH-P450 reductase,
and cytochrome b5, were provided in vials of 0.5 nmol dissolved in
100 mM of pH 7.4 phosphate buffered saline (PBS, from Sigma-
Aldrich) and used as received. Milli-Q water (18 MΩ/cm) was used
to prepare all aqueous solutions. All experiments were carried out in a
100 mM PBS solution (pH 7.4) as supporting electrolyte. NAP, was
purchased as a powder from Sigma-Aldrich. Due to its low solubility in
water, NAP solutions at different concentrations (50, 100, 150, 200,
250, 300 mM) were prepared by dissolving it in chromatography grade
methanol (Z99.9% from Sigma-Aldrich) before storing at 4 1C.
2.2. Apparatus
Electrochemical measurements were performed using an Auto-
lab electrochemical workstation (N Series Potentiostat/Galvano-
stat, Metrohm, Switzerland).
An Alzet model 1002 micro-osmotic pump (Durect corporation,
USA) of 0.6 cm diameter, 1.5 cm length and 90710 ml reservoir
volume with a nominal delivery pumping rate of 0.2570.05 ml/h
(in isotonic solution at 37 1C) was used to continuously deliver NAP.
2.3. Preparation of MWCNT/msCYP1A2 electrodes
MWCNT/msCYP1A2-SPEs were prepared according to Carrara
et al. (2011) and Baj-Rossi et al. (2012) by drop-casting 30 mg
of MWCNTs and three drops of msCYP1A2 (9 ml each drop).
The excess cytochrome was then removed by washing with milliQ
water. All the functionalized electrodes were stored in PBS at 4 1C
until use.
2.4. In vitro testing and serum collection from mice
Male C57BL/6 mice were used to extract serum samples. They
were intravenously injected with PBS. After 4 h, mice were
euthanized, blood harvested and left 1 h at room temperature.
The blood was collected and then centrifuged at 7000 rpm for
10 min at 4 1C; serum and supernatant were stored at 80 1C.
2.5. Electrochemical measurements
The electrochemical response of the biosensor was investigated
by cyclic voltammetry between 800 and 300 mV vs. Ag|AgCl at
20 mV/s at room temperature under aerobic conditions. For the
sensor calibration to NAP, the electrode was covered with 100 ml of
100 mM PBS (pH 7.4). Drug samples were added in 1 ml drops.
For the long-time continuous cyclic voltammetric measurements the
electrodes were placed in a stirred 10 ml of 100 mM PBS (pH 7.4).
For measurements with continuous NAP delivery, the micro-osmotic
pump was used in conjunction with the electrode in PBS. The micro-
osmotic pump was loaded with a 0.33 M NAP solution and the
experimental pumping rate was estimated equal to 0.1570.03 ml/h
(at 27 1C), which corresponds to a NAP delivery rate of 571 mM/h
(details on these calculations can be found in the Supplementary
materials).
Sensitivity per unit area was computed from the slope of the
straight line obtained by plotting peak current vs. drug concentration.
Peak current was estimated according to the procedure reported by
Carrara et al. (2009). The limit of detection (LOD) was computed
based on three times the signal-to-noise ratio according to the
expression (Mocak et al., 1997; Miller and Miller, 2010)
LOD¼ k δi
S
ð1Þ
where δi is the standard deviation of the blank measurements, S is
the detector sensitivity, and k is a parameter accounting for the
conﬁdence level (k¼1, 2, or 3 corresponds to 68.2%, 95.4%, or 99.6%
of statistical conﬁdence).
3. Results and discussion
3.1. Electrochemical response of the MWCNT/msCYP1A2-based drug
sensor
In CYP-biosensors, enzymes are immobilized on the electrode
surface that provides the electrons needed to drive the redox reaction
of the heme group of CYP, by replacing the natural redox partners
(Krishnan et al., 2011a). In cyclic voltammetry the redox reaction of the
heme group is recorded as reduction and oxidation current peaks.
Fig. S1 reports a typical voltammogram of msCYP1A2 on MWCNT-SPE
in aerobic conditions. According to the enzymatic kinetics, the cycle of
oxidation/reduction of the heme group is dependent on the substrate
concentration. Thus, in cyclic voltammetry the addition of a substrate
to a CYP electrode results in a further increase of the CYP reduction
current proportional to the substrate concentration (Shumyantseva
et al., 2004).
The oxidation/reduction of the heme group of CYP occurs at a
potential likely to be subjected to factors such as the electrode
preparation and immobilization technique employed for the CYP
(Johnson et al., 2005; Schneider and Clark, 2013).
In several reports, CYP1A2 peaks were detected at 380 mV
(Krishnan et al., 2011b), 265 mV (Antonini et al., 2003; Paternolli
et al., 2004), 280 mV (Estavillo et al., 2003), and 437 mV
(Shumyantseva et al., 2007). Even more complex is the situation
when microsomal CYPs are immobilized on electrodes. Since micro-
somal CYPs contain both the P450 enzyme and the NADPH-P450
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reductase (CPR), a contribution from each component can be present
in a voltammogram as reduction peaks. Recent works by Sultana
et al. (2005) and Mie et al. (2009) demonstrated that microsomal
CYPs show a CYP reduction peak at 380 mV and a CPR reduction
peak at 420 mV. Analogous potentials were found in other
individual studies on CPR electrochemistry (Shukla et al., 2006). It
is therefore necessary to identify in cyclic voltammetry the peak due
to the reduction of CYP that will increase in the presence of a
substrate.
Fig. 1A shows the resulting reduction peaks for a MWCNT/
msCYP1A2-SPE from the background subtracted voltammograms
at various NAP concentrations in an air saturated 100 mM PBS
solution (pH 7.4) at room temperature. Here the normalized values
of the current variations (positive y-axis) are reported. Cyclic
voltammograms were recorded before and after the NAP solution
was added to the PBS, in different concentrations (from 50 mM to
300 mM). Each voltammogram was background-subtracted to
exclude the contribution of CNT (Shobha Jeykumari et al., 2007).
The reduction peak region was isolated and ﬁtted by two Gaussian
functions centered at 560 mV and 380 mV (inset Fig. 1A). The
two peaks are attributed respectively to the CPR and CYP compo-
nents of microsome (Mie et al., 2009). The Gaussian functions
were then summed, varying height and amplitude to ﬁt the
current proﬁle obtained from the raw data, as already reported
by Carrara et al. (2009). The peak potentials showed a slight
positive shift with increasing NAP concentrations, while the
reduction current peak at 380 mV showed a clear linear
increase. These are typical behaviors of CYP in the presence of a
substrate (Johnson et al., 2005; Joseph et al., 2003), suggesting
that the peak at 380 mV is effectively ascribed to the catalytic
reduction of CYP1A2. As negative control, we performed cyclic
voltammetry with bare-SPE in the presence of NAP 300 mM (Fig. S2).
The reduction peak typical of a graphite SPE does not signiﬁcantly
change after the addition of the drug.
Fig. 1B shows the dependence of the peak current on NAP
concentration in PBS. The y-axis values are the reduction current
peaks obtained from cyclic voltammograms. The linear regression
equation is Ipc ¼ 0:124þ0:005CNAP , where Ipc (mA) is the reduction
peak current and CNAP (mM) is the NAP concentration, with a
correlation coefﬁcient of 0.99. The dynamic range of the MWCNT/
msCYP1A2-SPE sensor had an upper limit of 300 mM with a
sensitivity per unit area of 0.5470.02 mA/mMmm2. The corre-
sponding LOD was estimated to be 1671 mM based on a signal-to-
noise ratio of 3, which is included in NAP physiological range
(9–300 mM) (Upton et al., 1984).
The MWCNT/msCYP1A2-SPE sensor was also calibrated for NAP
detection in mouse serum (Fig. 1C). We obtained a sensitivity
comparable to the one obtained in PBS (0.670.2 mA/mMmm2),
but higher data variability (R2¼0.98), a lower linear range (up to
200 mM) and a higher LOD (33718 mM). The reason for these
differences is the complexity of the serum that generates inter-
ferences (Carrara et al., 2011).
3.2. Electrochemical behavior of the MWCNT/msCYP1A2-based
sensor in 36 h
An essential feature of a sensor for real-time drug monitoring is
the stability during continuous measurements. Few literature
reports studied CYP biosensor stability over a long time period
(Hendricks et al., 2009; Iwuoha et al., 2000), with the majority
showing the storage stability. Furthermore no studies have been
conducted on the CYP-based sensor stability during continuous
measurements.
The stability of the MWCNT/msCYP1A2-SPE sensor was ﬁrst
studied over 36 h. The sensor was incubated in 100 mM PBS (pH 7.4)
for 36 h and cyclic voltammograms were continuously acquired
every 90 min, to reduce the scans applied to CYP and saving its
catalytic activity. Cyclic voltammograms were recorded in aerobic
conditions and in the absence of any substrate. Fig. 2 depicts the
CYP1A2 reduction peak behavior at 380 mV in 36 h. The peak
shows good stability for the ﬁrst 16 h, and then starts to gradually
decrease, reaching about 70% of its initial height after 22 h, and
about 20% after 36 h. It is reasonable to explain the decrease of CYP
activity after 16 h with the enzyme degradation due to prolonged
use under continuous potential cycling, as previously demonstrated
in another study (Millo et al., 2009).
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Fig. 1. (A) Cyclic voltammetry reduction peak analysis after background subtraction at various NAP concentrations (from 50 mM to 300 mM) for a MWCNT/msCYP1A2-SPE.
The inset shows the reduction peak region (from 0 to 800 mV) ﬁtted by two Gaussian functions centered at 560 mV and 380 mV to describe the different faradic
contributes from microsomal CYP1A2 components. (B) Current response of the MWCNT/msCYP1A2-SPE sensor to different concentrations of NAP (conﬁdence interval 95.4%)
in PBS and (C) in mouse serum.
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3.3. Determination of NAP continuously delivered by an osmotic
pump
The sensor was employed to monitor the concentration variation
of NAP, which was continuously delivered in solution by means of a
micro-osmotic pump. After the micro-osmotic pump delivery rate
reached the steady state, cyclic voltammograms were acquired in
PBS, under aerobic conditions. The MWCNT/msCYP1A2-SPE sensor
was incubated in PBS for 36 h, while 571 mM/h of NAP was
constantly delivered (according to Eq. (1) in the Supplementary
materials).
After 16 h the MWCNT/msCYP1A2-SPE sensor starts losing its
activity. Fig. 3 shows the detection of NAP delivered by the osmotic
pump. The reduction current peaks measured with the sensor
every 2 h were transformed in NAP concentration (y-axis in Fig. 3),
according to the linear regression function obtained by the sensor
calibration (Fig. 1B). A fairly good linearity over a time lapse of 16 h
was obtained. The amount of NAP measured per hour estimated
from the linear regression analysis of the data shown in Fig. 3 was
6.270.2 mM/h, which is very close to the NAP delivery rate of the
osmotic pump previously estimated, 571 mM/h. These results
proved that the MWCNT/msCYP1A2-SPE sensor was able to
monitor the continuous delivery of NAP up to 16 h.
3.4. Repeatability and stability investigation of the MWCNT/
msCYP1A2-based sensor
The repeatability of the biosensing process was evaluated by
measuring the responses of freshly prepared biosensor to 200 mM
NAP within the ﬁrst 6 h of preparation at 1 h time interval, while
storing in PBS at 4 1C after each measurement. A relative standard
deviation (R.S.D.) value of 3.1% was obtained for the six measure-
ments, indicating good repeatability.
The reproducibility in electrochemical signals obtained using
three biosensors was evaluated by comparing the peak current on
continuous cycling (for 1 h) of the MWCNT/msCYP1A2-SPE sensor.
As expected, almost no obvious changes were found (R.S.D. value
of 4.4%).
The storage stability of the biosensor was investigated by mon-
itoring its response to 200 mM NAP with cyclic voltammograms after
storing in PBS at 4 1C for 0 h, 12 h, 24 h, 2 d, 4 d and 1 week. The peak
current decreased with increase in storage time. Nevertheless the
biosensor still retained 75% of its initial response after 1 week of
storage. An R.S.D. value of 11.2% was obtained for the 1-week stability
study. These results proved that the MWCNT/msCYP1A2-SPE sensor
had high reproducibility in the preparation procedure and it could be
repeatedly used in voltammetric determination.
4. Conclusions
A biosensor consisting of MWCNTs and microsomal CYP1A2
was developed for the continuous monitoring of NAP. The sensor
showed a stable response for 16 h of continuous measurements
and it was successfully applied to monitor the real-time monitor-
ing of NAP up to 16 h.
Results show that the electrochemical sensor provides high
sensitivity and extreme simplicity in sensor preparation, all
features that are suitable for the development of a point-of-care
sensor for continuous monitoring of pharmacological compounds.
Moreover the results presented in this article represent a novelty
since amperometric biosensors for continuous monitoring have
already been developed for glucose (Girardin et al., 2009), and
other endogenous compounds (Frost and Meyerhoff, 2002), but no
enzymatic amperometric biosensors have been reported so far for
real-time monitoring of drugs.
It is however important to say that taking into account the
complexity of the samples, we are planning for the future a more
complete validation of the device which will include the evalua-
tion of interferences, the analysis of real samples and the evalua-
tion of the accuracy of the method.
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